Erschienen in:
25.04.2023 | Main topic
RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
verfasst von:
Dr. med. Alexander Dutsch, Prof. Dr. Heribert Schunkert
Erschienen in:
Herz
|
Ausgabe 3/2023
Einloggen, um Zugang zu erhalten
Abstract
The COVID-19 pandemic led to an enormous burden on healthcare systems worldwide. Causal therapy is still in its infancy. Contrary to initial views that the use of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs) may increase the risk for a deleterious disease course, it has been shown that these agents may actually be beneficial for patients affected by COVID-19. In this article, we provide an overview of the three most commonly used classes of drugs in cardiovascular disease (ACEi/ARB, statins, beta-blockers) and their potential role in COVID-19 therapy. More results from randomized clinical trials are necessary to identify patients that can benefit most from the use of the respective drugs.